SCHEMBL15901852

SCHEMBL15901852

Cn1cc(C(=O)C(Cl)c2ccccc2)c2cc(F)ccc21

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.45
KDM4E B2RXH2 1/20 0.45
NR4A2 P43354 3/20 0.44
HAT1 O14929 2/20 0.42
EP300 Q09472 2/20 0.42
KMT2A Q03164 4/20 0.42
MEN1 O00255 2/20 0.42
POLB P06746 1/20 0.42
LMNA P02545 2/20 0.41
MITF O75030 1/20 0.41
MAPT P10636 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HTT P42858 1/20 0.41
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
CNR1 P21554 1/20 0.39
CNR2 P34972 1/20 0.39
PLA2G4A P47712 1/20 0.39
RIPK1 Q13546 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5539343 0.85 POLB (0.57) ALDH1A1KDM4ENR4A2HAT1EP300
SCHEMBL14831344 0.83 HTR3A (0.51) KMT2AMEN1PLA2G4A
SCHEMBL15902348 0.81 CNR2 (0.48) HAT1EP300KMT2AMEN1CNR1
SCHEMBL2433258 0.79 KDM4E (0.55) ALDH1A1KDM4ENR4A2KMT2AMEN1
SCHEMBL15902295 0.79 CNR1 (0.42) POLBLMNAMAPTNPSR1CNR1
SCHEMBL4009106 0.76 ALDH1A1 (0.53) ALDH1A1KDM4ENR4A2KMT2AMEN1
SCHEMBL25742062 0.76 ALDH1A1 (0.47) ALDH1A1KDM4ENR4A2POLBRIPK1
SCHEMBL14832011 0.76 POLB (0.49) ALDH1A1KDM4ENR4A2HAT1EP300
SCHEMBL7275971 0.76 KDM4E (0.55) ALDH1A1KDM4ENR4A2KMT2AMEN1
SCHEMBL25742028 0.75 KDM4E (0.46) ALDH1A1KDM4EKMT2AMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12012411-B2 Viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2024-06-18 US disclosed
US-20220106321-A1 VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-04-07 US disclosed
US-11279704-B2 Viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-03-22 US disclosed
CN-108440370-B Inhibitors of viral replication 鲁汶天主教大学 2021-07-30 CN disclosed
EP-3617192-A1 VIRAL REPLICATION INHIBITORS Katholieke Universiteit Leuven K.U. Leuven R&D (BE) 2020-03-04 EP disclosed
US-10550123-B2 Viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2020-02-04 US disclosed
US-20190337954-A1 VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2019-11-07 US disclosed
EP-2760831-B1 VIRAL REPLICATION INHIBITORS UNIV LEUVEN KATH (BE) 2019-08-07 EP disclosed
US-20140213586-A1 VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2014-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140213586-A1 VIRAL REPLICATION INHIBITORS EIF2AK2, MAVS, ZC3HAV1 ALDH1A1 4277/4885KDM4E 1372/4885NR4A2 3844/4885
US-11279704-B2 Viral replication inhibitors EIF2AK2, MAVS, ZC3HAV1 ALDH1A1 4277/4885KDM4E 1372/4885NR4A2 3844/4885
US-20190337954-A1 VIRAL REPLICATION INHIBITORS EIF2AK2, MAVS, ZC3HAV1 ALDH1A1 4277/4885KDM4E 1372/4885NR4A2 3844/4885
US-10550123-B2 Viral replication inhibitors EIF2AK2, MAVS, ZC3HAV1 ALDH1A1 4277/4885KDM4E 1372/4885NR4A2 3844/4885
US-20220106321-A1 VIRAL REPLICATION INHIBITORS EIF2AK2, MAVS, ZC3HAV1 ALDH1A1 4277/4885KDM4E 1372/4885NR4A2 3844/4885
US-12012411-B2 Viral replication inhibitors EIF2AK2, MAVS, ZC3HAV1 ALDH1A1 4277/4885KDM4E 1372/4885NR4A2 3844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.